Compare Apple Inc (AAPL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Apple Inc trades at $313.3 (market cap $4.56T), while Regeneron Pharmaceuticals Inc trades at $662.85 (market cap $70.90B). The key difference: Apple Inc is far larger — about 64.3× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.56%). Which is the better fit depends on your goals.
| AAPL | REGN | |
|---|---|---|
Market Cap | $4.56T | $70.90B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $812.27 |
52-Week Low | $202.38 | $542.52 |
Enterprise Value | $4.58T | $64.85B |
Dividend Yield | 0.35% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $313.28, up 0.2% with strong technical momentum and bullish moving average signals. The company reported robust Q1 2026 earnings of $2.01 EPS, beating estimates, with revenue growth accelerating to $416.16B in 2025. Analyst consensus remains positive with 63% buy ratings and a $329.62 price target. Recent news highlights Apple's AI potential through its 2.5 billion device ecosystem and partnership with Alphabet's Gemini.
Apple demonstrates strong fundamental performance with expanding profit margins and consistent earnings beats. The stock offers upside to analyst targets but faces risks from potential Q2 earnings miss, union disputes, and regulatory pressures. Valuation multiples remain elevated, requiring sustained growth to justify current levels.
Regeneron (REGN) trades at $676.23, up 3.36% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $9.47 exceeding the $8.91 forecast. Revenue grew to $14.34B in 2025, with a net income margin of 29.65%. Recent FDA acceptance of cemdisiran for gMG and inclusion in a manufacturing review pilot program highlight positive regulatory developments.
Outlook remains positive given earnings momentum and analyst consensus, but risks include regulatory scrutiny and competitive pressures. The consensus price target of $778.29 implies 15% upside, supported by 32 buy ratings and no sells. However, legal investigations and reliance on key drug portfolios warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
